Exploration of individuality in drug metabolism by high-throughput metabolomics: The fast line for personalized medicine.

[1]  Nicola Zamboni,et al.  High-throughput discovery metabolomics. , 2015, Current opinion in biotechnology.

[2]  C. Borchers,et al.  Metabolic profiling of bile acids in human and mouse blood by LC-MS/MS in combination with phospholipid-depletion solid-phase extraction. , 2015, Analytical chemistry.

[3]  Mingshe Zhu,et al.  Applications of mass spectrometry in drug metabolism: 50 years of progress* , 2015, Drug metabolism reviews.

[4]  A. Shevchenko,et al.  Systematic screening for novel lipids by shotgun lipidomics. , 2014, Analytical chemistry.

[5]  D. Laifenfeld,et al.  Systems diagnostics: anticipating the next generation of diagnostic tests based on mechanistic insight into disease. , 2014, Drug discovery today.

[6]  R A Knight,et al.  DRUGSURV: a resource for repositioning of approved and experimental drugs in oncology based on patient survival information , 2014, Cell Death and Disease.

[7]  R. Knight,et al.  Large scale integration of drug-target information reveals poly-pharmacological drug action mechanisms in tumor cell line growth inhibition assays , 2014, Oncotarget.

[8]  Alexander G. Camenzind,et al.  Mass spectrometry in high-throughput clinical biomarker assays: multiple reaction monitoring. , 2014, Topics in current chemistry.

[9]  R. Tukey,et al.  Intestinal glucuronidation protects against chemotherapy-induced toxicity by irinotecan (CPT-11) , 2013, Proceedings of the National Academy of Sciences.

[10]  A. Archakov,et al.  Postgenomics diagnostics: metabolomics approaches to human blood profiling. , 2013, Omics : a journal of integrative biology.

[11]  Meicun Yao,et al.  Identification of urinary metabolites of imperatorin with a single run on an LC/Triple TOF system based on multiple mass defect filter data acquisition and multiple data mining techniques , 2013, Analytical and Bioanalytical Chemistry.

[12]  Karen S. Frese,et al.  Next-Generation Sequencing: From Understanding Biology to Personalized Medicine , 2013, Biology.

[13]  Michael P Snyder,et al.  High-throughput sequencing for biology and medicine , 2013, Molecular systems biology.

[14]  Rebecca Kirk.  Targeted therapies: The toxic reality of new drugs , 2012, Nature Reviews Clinical Oncology.

[15]  Nicola Zamboni,et al.  High-throughput, accurate mass metabolome profiling of cellular extracts by flow injection-time-of-flight mass spectrometry. , 2011, Analytical chemistry.

[16]  L. Natarajan,et al.  Tamoxifen Metabolite Concentrations, CYP2D6 Genotype, and Breast Cancer Outcomes , 2011, Clinical pharmacology and therapeutics.

[17]  Ralf J. M. Weber,et al.  Characterization of isotopic abundance measurements in high resolution FT-ICR and Orbitrap mass spectra for improved confidence of metabolite identification. , 2011, Analytical chemistry.

[18]  M. Ingelman-Sundberg,et al.  Genetic polymorphism and toxicology--with emphasis on cytochrome p450. , 2011, Toxicological sciences : an official journal of the Society of Toxicology.

[19]  M. Baker.  Metabolomics: from small molecules to big ideas , 2011, Nature Methods.

[20]  F. Collins,et al.  The path to personalized medicine. , 2010, The New England journal of medicine.

[21]  R. Schilsky.  Personalized medicine in oncology: the future is now , 2010, Nature Reviews Drug Discovery.

[22]  M. Pirmohamed,et al.  Drug-induced hypersensitivity reactions and pharmacogenomics: past, present and future. , 2010, Pharmacogenomics.

[23]  Jun Han,et al.  Mass spectrometry-based technologies for high-throughput metabolomics. , 2009, Bioanalysis.

[24]  Donglu Zhang,et al.  Mass defect filter technique and its applications to drug metabolite identification by high-resolution mass spectrometry. , 2009, Journal of mass spectrometry : JMS.

[25]  Federico Innocenti,et al.  Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Alexey V Antonov,et al.  TICL – a web tool for network‐based interpretation of compound lists inferred by high‐throughput metabolomics , 2009, The FEBS journal.

[27]  Donglu Zhang,et al.  Mass defect profiles of biological matrices and the general applicability of mass defect filtering for metabolite detection. , 2008, Rapid communications in mass spectrometry : RCM.

[28]  C. Junot,et al.  Direct introduction of biological samples into a LTQ-Orbitrap hybrid mass spectrometer as a tool for fast metabolome analysis. , 2008, Analytical chemistry.

[29]  I. Rusyn,et al.  Towards high-throughput metabolomics using ultrahigh-field Fourier transform ion cyclotron resonance mass spectrometry , 2008, Metabolomics.

[30]  Amin Rostami-Hodjegan,et al.  Simulation and prediction of in vivo drug metabolism in human populations from in vitro data , 2007, Nature Reviews Drug Discovery.

[31]  Rainer Breitling,et al.  Ab initio prediction of metabolic networks using Fourier transform mass spectrometry data , 2006, Metabolomics.

[32]  Walter A. Korfmacher,et al.  Principles and applications of LC-MS in new drug discovery. , 2005, Drug discovery today.

[33]  J. Flaws,et al.  Association of Tamoxifen (TAM) and TAM Metabolite Concentrations with Self-Reported Side Effects of TAM in Women with Breast Cancer , 2004, Breast Cancer Research and Treatment.

[34]  Soma Das,et al.  Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  G. Pelosi,et al.  Tamoxifen and Metabolite Concentrations in Serum and Breast Cancer Tissue during Three Dose Regimens in a Randomized Preoperative Trial , 2004, Clinical Cancer Research.

[36]  T. Baillie,et al.  Integration of knowledge-based metabolic predictions with liquid chromatography data-dependent tandem mass spectrometry for drug metabolism studies: application to studies on the biotransformation of indinavir. , 2004, Analytical chemistry.

[37]  M. Pirmohamed,et al.  Metabolic activation in drug allergies. , 2001, Toxicology.

[38]  中尾 光輝,et al.  KEGG(Kyoto Encyclopedia of Genes and Genomes)〔和文〕 (特集 ゲノム医学の現在と未来--基礎と臨床) -- (データベース) , 2000 .

[39]  V. Jordan,et al.  Metabolites of tamoxifen in animals and man: Identification, pharmacology, and significance , 1982, Breast cancer research and treatment.

[40]  H. Rochefort,et al.  Tamoxifen and metabolites in MCF7 cells: correlation between binding to estrogen receptor and inhibition of cell growth. , 1982, Cancer research.

[41]  A. Sjoerdsma,et al.  Studies on the Metabolism and Mechanism of Action of Methyldopa , 1963, Circulation.